Raymond James Financial Inc. bought a new stake in shares of STAAR Surgical (NASDAQ:STAA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 38,017 shares of the medical instruments supplier's stock, valued at approximately $923,000. Raymond James Financial Inc. owned approximately 0.08% of STAAR Surgical as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quarry LP bought a new stake in STAAR Surgical in the third quarter valued at $50,000. FMR LLC increased its position in shares of STAAR Surgical by 79.3% during the third quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier's stock valued at $263,000 after buying an additional 3,136 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of STAAR Surgical during the fourth quarter valued at about $292,000. HighTower Advisors LLC bought a new position in STAAR Surgical in the third quarter worth about $336,000. Finally, XTX Topco Ltd purchased a new stake in STAAR Surgical in the third quarter worth about $508,000. Institutional investors own 96.70% of the company's stock.
STAAR Surgical Stock Performance
Shares of STAA traded up $0.78 during midday trading on Wednesday, hitting $15.87. 1,927,178 shares of the company traded hands, compared to its average volume of 786,240. STAAR Surgical has a 52 week low of $13.50 and a 52 week high of $51.81. The firm has a 50 day moving average of $17.94 and a 200-day moving average of $24.22. The stock has a market cap of $782.79 million, a price-to-earnings ratio of -38.71 and a beta of 0.75.
Insider Activity at STAAR Surgical
In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 21,155 shares of the stock in a transaction on Tuesday, January 14th. The stock was acquired at an average price of $21.46 per share, for a total transaction of $453,986.30. Following the completion of the transaction, the insider now directly owns 10,869,786 shares of the company's stock, valued at $233,265,607.56. This trade represents a 0.20 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders bought 1,763,757 shares of company stock valued at $28,914,625. Insiders own 1.00% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on the company. Piper Sandler lowered their target price on STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating for the company in a research note on Wednesday, February 12th. StockNews.com cut shares of STAAR Surgical from a "hold" rating to a "sell" rating in a report on Thursday, February 13th. BTIG Research downgraded shares of STAAR Surgical from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 12th. William Blair cut shares of STAAR Surgical from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 12th. Finally, Needham & Company LLC restated a "hold" rating on shares of STAAR Surgical in a report on Thursday, February 27th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $25.29.
Get Our Latest Research Report on STAA
About STAAR Surgical
(
Free Report)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Further Reading
Before you consider STAAR Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.
While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn how options trading can help you navigate market volatility, manage risk, and maximize returns with MarketBeat's "Unlock the Potential in Options Trading." Click the link below to have this special report delivered to your inbox.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
